癌バイオマーカーの市場規模・シェア・展望・機会 (2022年～2030年)：バイオマーカータイプ・癌タイプ・エンドユーザー・地域別

癌の早期診断のため、潜在的な癌バイオマーカーの開発・同定に向けたR&D活動が活発化しており、近い将来の世界の癌バイオマーカー市場の成長を促進すると予想されています。

当レポートでは、世界の癌バイオマーカーの市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、技術動向、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 市場動向
• 最近の展開
• 買収・提携シナリオ
• 技術概要
• 規制シナリオ
• PEST分析

第4章 世界の癌バイオマーカー市場：COVID-19の影響

• 全体的な影響
• 需要と供給への影響
• COVID-19：市場への影響

第5章 世界の癌バイオマーカー市場：バイオマーカータイプ別

• 概要
• タンパク質バイオマーカー
• 遺伝子バイオマーカー
• その他

第6章 世界の癌バイオマーカー市場：癌タイプ別

• 概要
• 乳癌
• 肺癌
• 前立腺癌
• 腎臓癌
• 肝臓癌
• その他

第7章 世界の癌バイオマーカー市場：エンドユーザー別

• 概要
• 病院
• 学術・癌研究機関
• 外来手術センター
• 癌診断ラボ

第8章 世界の癌バイオマーカー市場：地域別

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• bioMerieux, Inc.
• INOVIQ
• Bio-Rad Laboratories, Inc.
• Abbott
• Becton, Dickinson and Company
• Merck KGaA
• QIAGEN
• Thermo Fisher Scientific Inc.
• CENTOGENE N.V.
• PerkinElmer Inc.
• Siemens Healthcare Private Limited

第10章 セクション

Cancer biomarkers offers great opportunity in improving management of cancer patients by enhancing the efficiency of detection and efficacy of the treatment. Biomarkers of cancer includes various biochemical components such as proteins, sugars, lipids, nucleic acids, small metabolites, cytogenetic and cytokinetic parameters, and whole tumor cells, which are found in body fluid. Molecular alterations used for cancer diagnosis involves application of DNA, RNA, microRNAs, and proteins.

Biomarker testing is a way to look for genes, proteins, and other substances (called biomarkers or tumor markers) that can provide information about cancer. Each person's cancer has a unique pattern of biomarkers. Some biomarkers affect how certain cancer treatments work. Biomarker testing may help the doctor choose a cancer treatment for you. Biomarker testing for cancer treatment may also be called: tumor testing, tumor genetic testing, genomic testing or genomic profiling, molecular testing or molecular profiling, somatic testing, and tumor subtyping. Biomarker testing is different from genetic testing that is used to find out if someone has inherited mutations that make them more likely to get cancer. Inherited mutations are those you are born with. They are passed on to an individual by parents.

Market Dynamics

Increasing research and development activities in the field of cancer biomarker to develop and identify potential cancer biomarkers for early diagnosis of cancer, is expected to drive growth of the global cancer biomarkers market, in the near future. For instance, in March 2018, a team of researchers from University of Massachusetts and Clarkson University discovered various protein such as human chorionic gonadotropin (hCG), lipoproteins, α1-chymotrypsin and α1-antitrypsin from breast milk, which can act as a potential cancer biomarker in detection of breast cancer.

Key features of the study:

• This report provides an in-depth analysis of the global cancer biomarkers market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include bioMerieux, Inc., INOVIQ, Bio-Rad Laboratories, Inc., Abbott, Becton, Dickinson and Company, Merck KgaA, QIAGEN, Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., and Siemens Healthcare Private Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market

Detailed Segmentation:

• Global Cancer Biomarkers Market, By Biomarker Type:
  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers
• Global Cancer Biomarkers Market, By Cancer Type:
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Liver Cancer
  • Other Cancers
• Global Cancer Biomarkers Market, By End User:
  • Hospitals
  • Academic and Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Cancer Diagnostic Laboratories
• Global Cancer Biomarkers Market, By Region:
  • North America
    • By Country
    • U.S.
    • Canada
  • Latin America
    • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Country
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • bioMerieux, Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • INOVIQ
  • Bio-Rad Laboratories, Inc.
  • Abbott
  • Becton, Dickinson and Company
  • Merck KGaA
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • CENTOGENE N.V.
  • PerkinElmer Inc.
  • Siemens Healthcare Private Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Biomarker Type
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• PEST Analysis

4. Global Cancer Biomarkers Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global Cancer Biomarkers Market, By Biomarker Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Protein Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Genetic Biomarkers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Other Cancer Biomarkers

6. Global Cancer Biomarkers Market, By Cancer Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Kidney Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Liver Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Other Cancers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Cancer Biomarkers Market, By End User, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2018 - 2030
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Academic and Cancer Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Ambulatory Surgical Centers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Cancer Diagnostic Laboratories
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Cancer Biomarkers Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

• bioMerieux, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• INOVIQ
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bio-Rad Laboratories, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Becton, Dickinson and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• QIAGEN
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Thermo Fisher Scientific Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CENTOGENE N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PerkinElmer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Siemens Healthcare Private Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us